Peptinov’s immunotherapy approach can be applied to many non-infectious diseases (auto-immune and inflammatory diseases, cancer, chronic pain). It has the potential to provide a complementary approach to monoclonal antibodies in large populations with limited access to biologics. The effect duration of Peptinov’s immunotherapies is temporary (3-4 months). Consequently the immunotherapies must be administered several times per year. Their production costs are very low.



Peptinov’s active inmmunization approach

Peptinov’s breakthrough active immunization approach uses tailored peptide-based immunotherapies, derived from target self proteins.

These peptides which are selected and designed using an array of bioinformatics tools (trade secret) are designed to induce the production of antibodies directed against the targeted proteins after immunization. The produced antibodies neutralize the biological activity of the target protein.

In doing so, Peptinov’s immunotherapies have a similar action compared to monoclonal antibodies.

This approach present several advantages:

  • very low production costs
  • ease of use
  • potentially no resistance to treatment.

Peptinov’s anti-IL-6 immunotherapy is the most advanced product in the R&D pipeline and is currently being evaluated in regulatory pre-clinical development (toxicology studies).


Capini et al. Active immunization against murine TNFα peptides in mice: generation of endogenous antibodies cross-reacting with the native cytokine and in vivo protection. Vaccine. 2004;22(23-24):3144-53. PMID: 15297057.

Bertin-Maghit et al. Improvement of collagen-induced arthritis by active immunization against murine IL-1beta peptides designed by molecular modelling. Vaccine. 2005;23(33):4228-35. PMID: 16005738.

Ratsimandresy et al. Active immunization against IL-23p19 improves experimental arthritis. Vaccine. 2011;29(50):9329-36. PMID: 22008816.

Desallais et al. Targeting IL-6 by both passive or active immunization strategies prevents bleomycin-induced skin fibrosis. Arthritis Res Ther. 2014;16(4):R157. PMID: 25059342

Desallais et al. Immunization against an IL-6 peptide induces anti-IL-6 antibodies and modulates the Delayed-Type Hypersensitivity reaction in cynomolgus monkeys. Scientific Reports. 2016 Jan 19;6:19549. PMID: 26782790